Top Abstracts with Expert Perspective: Plasma Cell Dyscrasias (Myeloma, Amyloidosis etc)
Tracks
-
| Monday, April 28, 2025 |
| 8:00 AM - 9:30 AM |
| BSH Stage (Hall 4) |
Speaker
Prof. Graham Jackson
Consultant Haematologist
Newcastle University
Long term outcomes of the Myeloma XI trial comparing lenalidomide maintenance to observation after ASCT.
8:00 AM - 8:15 AM
Dr Mamta Garg
Consultant Haematologist
University Hospitals Leicester
Belantamab Mafodotin+Bortezomib+Dexamethasone vs Daratumumab+Vd in RRMM: Updates on Overall Survival and Efficacy in DREAMM-7
8:15 AM - 8:30 AM
Dr Rakesh Popat
Consultant Haematologist
University College London Hospitals NHS Foundation Trust
Overall Survival With Ciltacabtagene Autoleucel Versus Standard of Care in Lenalidomide-Refractory Multiple Myeloma: CARTITUDE-4 Update
8:30 AM - 8:45 AM
Dr Victoria Campbell
Consultant Haematologist
Western General Hospital
Tolerability and Clinical Activity of Novel First-In-Class Oral Agent, inobrodib (CCS1477) With Pom-Dex in RRMM
8:45 AM - 9:00 AM
Prof. Ashutosh Wechalekar
Consultant Haematologist
Royal Free Hospital
Daratumumab + Bortezomib/Cyclophosphamide/ Dexamethasone In Newly Diagnosed AL Amyloidosis: OS and Final MOD-PFS: ANDROMEDA Study
9:00 AM - 9:15 AM
Miss Rachel Senior
Advanced Clinical Pharmacist - Haematology
Leeds Teaching Hospitals NHS Trust
Ambulatory Elranatamab Step-Up is Safe and Deliverable: The Leeds Teaching Hospitals Experience
9:15 AM - 9:30 AMChair
Kevin Boyd
Consultant Haematologist
The Royal Marsden Nhs Foundation Trust
